These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 16135481

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    Urol Clin North Am; 2007 May; 34(2):219-25; abstract ix-x. PubMed ID: 17484926
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD, Foster RS, Bihrle R, Donohue JP.
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T, Kawakita M, Terachi T, Habuchi T, Ogawa O, Kamoto T.
    J Surg Oncol; 2006 Dec 01; 94(7):619-23. PubMed ID: 17111392
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
    Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER, Einhorn LH, Roth BJ, Donohue JP.
    Urology; 1997 Dec 01; 50(6):957-62. PubMed ID: 9426730
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B, Carver BS, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J.
    BJU Int; 2007 May 01; 99(5):993-7. PubMed ID: 17437432
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD, Patel MI, Sheinfeld J.
    J Urol; 2004 Jan 01; 171(1):168-71. PubMed ID: 14665869
    [Abstract] [Full Text] [Related]

  • 14. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.
    J Clin Oncol; 2005 Apr 20; 23(12):2781-8. PubMed ID: 15837993
    [Abstract] [Full Text] [Related]

  • 15. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL.
    Urology; 2007 Dec 20; 70(6):1173-8. PubMed ID: 18158041
    [Abstract] [Full Text] [Related]

  • 16. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
    Matveev VB, Volkova MI, Cherniev VA, Figurin KM, Mitin AV.
    Urologiia; 2010 Dec 20; (3):41-7. PubMed ID: 20734877
    [Abstract] [Full Text] [Related]

  • 17. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH.
    Cancer; 2007 Sep 15; 110(6):1235-40. PubMed ID: 17665498
    [Abstract] [Full Text] [Related]

  • 18. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR, Belitsky P, Millard OH, Lannon SG.
    Can J Surg; 1993 Dec 15; 36(6):537-40. PubMed ID: 7504978
    [Abstract] [Full Text] [Related]

  • 19. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J.
    J Clin Oncol; 2007 Mar 20; 25(9):1033-7. PubMed ID: 17261854
    [Abstract] [Full Text] [Related]

  • 20. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
    Peterson M, Beck S, Bihrle R, Einhorn L, Foster R.
    BJU Int; 2009 Jul 20; 104(2):176-8. PubMed ID: 19493258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.